Literature DB >> 18789716

Relationship of elevated osteoprotegerin with insulin resistance, CRP, and TNF-alpha levels in men with type 2 diabetes.

Subhashini Yaturu1, Justin Rains, Sushil K Jain.   

Abstract

AIM: Our objective of this study is to investigate the relationship between plasma osteoprotegerin (OPG) levels in type 2 diabetes and its relationship with the insulin resistance, HbA(1c), CRP, and TNF-alpha levels.
METHODS: In a cross-sectional study, levels of OPG were determined in 50 subjects with type 2 diabetes and 59 control subjects without diabetes. The OPG levels between the groups were compared and their correlation with insulin resistance, glycemia and inflammatory markers CRP and TNF-alpha was determined.
RESULTS: OPG levels were elevated in subjects with diabetes (6.8+/-0.27 pmol/l), compared to control subjects (5.7+/-0.26 pmol/l). OPG levels significantly correlate with insulin, insulin resistance, CRP, and TNF-alpha.
CONCLUSION: OPG levels are significantly correlated with insulin resistance and may reflect the proinflammatory state in type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18789716     DOI: 10.1016/j.cyto.2008.07.471

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  18 in total

1.  Serum osteoprotegerin: bone or cardiovascular marker in Type 2 diabetes males?

Authors:  P Rozas Moreno; R Reyes García; A García-Martín; M Varsavsky; J A García-Salcedo; M Muñoz-Torres
Journal:  J Endocrinol Invest       Date:  2012-02-28       Impact factor: 4.256

2.  Effects of physiological variations in circulating insulin levels on bone turnover in humans.

Authors:  Rita Basu; James Peterson; Robert Rizza; Sundeep Khosla
Journal:  J Clin Endocrinol Metab       Date:  2011-02-16       Impact factor: 5.958

3.  Soluble receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation.

Authors:  Chun-Hsiung Chen; Hung-An Chen; Hsien-Tzung Liao; Chin-Hsiu Liu; Chang-Youh Tsai; Chung-Tei Chou
Journal:  Clin Rheumatol       Date:  2010-08-06       Impact factor: 2.980

4.  Comparison of osteoprotegerin and vascular endothelial growth factor in normoalbuminuric Type 1 diabetic and control subjects.

Authors:  A Esteghamati; A Arefzadeh; A Zandieh; M Salehi Sadaghiani; S Noshad; M Nakhjavani
Journal:  J Endocrinol Invest       Date:  2013 Jul-Aug       Impact factor: 4.256

5.  Relation of Osteoprotegerin, Visfatin and Ghrelin to Metabolic Syndrome in Type 2 Diabetic Patients.

Authors:  Manal Basyouni Ahmed; Maha Imam Ahmed Ismail; Abdel-Raheim M Meki
Journal:  Int J Health Sci (Qassim)       Date:  2015-04

6.  The association of insulin resistance with serum osteoprotegerin in obese adolescents.

Authors:  Joanna Suliburska; Pawel Bogdanski; Ewa Gajewska; Grazyna Kalmus; Magdalena Sobieska; Wlodzimierz Samborski
Journal:  J Physiol Biochem       Date:  2013-05-22       Impact factor: 4.158

7.  Secretion patterns of circulating osteoprotegerin and response to acute and chronic energy deprivation in young healthy adults.

Authors:  Konstantinos N Aronis; Joo-Pin Foo; John P Chamberland; Christos S Mantzoros
Journal:  J Clin Endocrinol Metab       Date:  2012-05-04       Impact factor: 5.958

Review 8.  Osteoprotegerin in Cardiometabolic Disorders.

Authors:  C Pérez de Ciriza; A Lawrie; N Varo
Journal:  Int J Endocrinol       Date:  2015-05-11       Impact factor: 3.257

9.  Expression of osteoprotegerin in placenta and its association with preeclampsia.

Authors:  Pei Shen; Yunhui Gong; Tao Wang; Yueyue Chen; Jin Jia; Shanshan Ni; Bin Zhou; Yapin Song; Lin Zhang; Rong Zhou
Journal:  PLoS One       Date:  2012-08-30       Impact factor: 3.240

10.  Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes.

Authors:  Minoru Yamaoka; Yusuke Ono; Masahide Ishizuka; Kouichi Yasuda; Takashi Uematsu; Kiyofumi Furusawa
Journal:  Clin Cosmet Investig Dent       Date:  2009-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.